De Smedt Magda, Hoebeke Inge, Plum Jean
Department of Clinical Chemistry, Microbiology and Immunology, Faculty of Medicine and Health Sciences, University Hospital Ghent, Ghent University, B9000 Ghent, Belgium.
Blood Cells Mol Dis. 2004 Nov-Dec;33(3):227-32. doi: 10.1016/j.bcmd.2004.08.007.
In this paper, we confirm data reported by the group of Zúñiga-Pflücker that human cord blood CD34(+)38(-)Lin- progenitor cells when co-cultured with the murine stromal cell line OP9-DL engineered to express the Notch ligand delta-like-1 mature into T lymphocytes with a phenotypic progression as the one seen in thymus. We show that this is also the case for human T cells starting from CD34(+) adolescent bone marrow cells. These findings offer the theoretical possibility to generate ex vivo human T cells and administer them in vivo in patients to overcome their immune deficient window period after transplantation. However, the practical and theoretical problems that this new technology has to overcome before this technique can be applied in clinic are still enormous and discussed.
在本文中，我们证实了祖尼加 - 普弗勒克团队报告的数据，即人脐带血CD34(+)38(-)Lin-祖细胞与经基因工程改造以表达Notch配体delta样-1的小鼠基质细胞系OP9-DL共培养时，会成熟为T淋巴细胞，其表型进展与胸腺中所见的情况相同。我们还表明，从CD34(+)青少年骨髓细胞开始的人T细胞也是如此。这些发现为体外产生人T细胞并将其体内给予患者以克服移植后的免疫缺陷窗口期提供了理论可能性。然而，在该技术能够应用于临床之前，这项新技术必须克服的实际和理论问题仍然巨大，本文对此进行了讨论。
